Cytokines in cancer immunity and immunotherapy

Immunological Reviews

Volumn 202, Issue , 2004, Pages 275-293

  Smyth, Mark J ^a   Cretney, Erika ^a   Kershaw, Michael H ^a   Hayakawa, Yoshihiro ^a  

^a P MacCallum Cancer Ctr   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CISPLATIN; COLONY STIMULATING FACTOR 1; CYTOKINE; DACARBAZINE; FAS LIGAND; FLT3 LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; MELAN A; PERFORIN; PROTEIN P40; RAG2 PROTEIN; STAT1 PROTEIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VASCULOTROPIN;

CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CARCINOGENESIS; CELL TRANSFORMATION; CHILL; CLINICAL TRIAL; DOSE RESPONSE; FATIGUE; FEVER; HEADACHE; HUMAN; HYPOTENSION; IMMUNE SYSTEM; INFLAMMATION; METASTASIS; MOUSE; MULTIPLE ORGAN FAILURE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TUMOR IMMUNITY; VOMITING;

ANIMALS; CYTOKINES; IMMUNOTHERAPY; INFLAMMATION; INTERFERONS; MICE; NEOPLASMS;

EID: 9644278053     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00199.x     Document Type: Review

References (208)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
2. Rosenberg SA, Lotze MT. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 1986;4:681-709.
3. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
4. Forni G, et al. Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metastasis Rev 1988;7:289-309.
5. Dranoff G, Mulligan RC. Gene transfer as cancer therapy. Adv Immunol 1995;58:417-454.
6. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002;188:147-154.
7. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155-168.
8. Gresser I, Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 2002;13:111-118.
9. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:119-134.
10. Apte RN, Voronov E. Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 2002;12:277-290.
11. Ferrantini M, Belardelli F. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin Cancer Biol 2000;10:145-157.
12. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res 1999;19:1069-1098.
13. Pfeffer LM, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998;58:2489-2499.
14. Trinchieri G, Santoli D, Granato D, Perussia B. Antagonistic effects of interferons on the cytotoxicity mediated by natural killer cells. Fed Proc 1981;40:2705-2710.
15. Biron CA, Sonnenfeld G, Welsh RM. Interferon induces natural killer cell blastogenesis in vivo. J Leukoc Biol 1984;35:31-37.
16. Ortaldo JR, Phillips W, Wasserman K, Herberman RB. Effects of metabolic inhibitors on spontaneous and interferon-boosted human natural killer cell activity. J Immunol 1980;125:1839-1844.
17. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I Interferon in vivo. Science 1996;272:1947-1950.
18. Finkelman FD, et al. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J Exp Med 1991;174:1179-1188.
19. Fellous M, Nir U, Wallach D, Merlin G, Rubinstein M, Revel M. Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells. Proc Natl Acad Sci USA 1982;79:3082-3086.
20. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994;265:106-109.
21. Taguchi Y, Purtilo DT, Okano M. The effect of intravenous immunoglobulin and interferon-alpha on Epstein-Barr virus-induced lymphoproliferative disorder in a liver transplant recipient. Transplantation 1994;57:1813-1815.
22. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994;1:447-456.
23. Kaplan DH, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-7561.
24. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002;196:129-134.
25. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001;97:192-197.
26. Enzler T, et al. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med 2003;197:1213-1219.
27. Hayashi T, Faustman DL. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Res 2002;62:24-27.
28. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-276.
29. Brunda MJ, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-1230.
30. Smyth MJ, Taniguchi M, Street SE. The antitumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000;165:2665-2670.
31. Musiani P, et al. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today 1997;18:32-36.
32. Di Carlo E, et al. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Clin Cancer Res 2001;7:830s-837s.
33. Noguchi Y, Richards EC, Chen YT, Old LJ. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 1995;92:2219-2223.
34. Kawano T, et al. CD1d-restricted and TCR-mediated activation of valpha 14 NKT cells by glycosylceramides. Science 1997;278:1626-1629.
35. Smyth MJ, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-668.
36. Noguchi Y, Jungbluth A, Richards EC, Old LJ. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci USA 1996;93:11798-11801.
37. Hayakawa Y, Rovero S, Forni G, Smyth MJ. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 2003;100:9464-9469.
38. Boggio K, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998;188:589-596.
39. Roy EJ, Gawlick U, Orr BA, Rund LA, Webb AG, Kranz DM. IL-12 treatment of endogenously arising murine brain tumors. J Immunol 2000;165:7293-7299.
40. Lo CH, et al. Antitumor and antimetastatic activity of IL-23. J Immunol 2003;171:600-607.
41. Takeda K, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100.
42. Smyth MJ, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661-670.
43. Takeda K, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195:161-169.
44. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002;168:1356-1361.
45. Smyth MJ, Thia KT, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000;192:755-760.
46. Schmaltz C, et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 2002;8:1433-1437.
47. Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 1998;187:1825-1838.
48. Straus SE, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001;98:194-200.
49. Yu P, et al. Priming of naïve T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004;5:141-149.
50. Dranoff G, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
51. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-965.
52. Fernandez NC, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-411.
53. Maliszewski C. Dendritic cells in models of tumor immunity. Role of Flt3 ligand. Pathol Biol (Paris) 2001;49:481-483.
54. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-2368.
55. Chang AE, Rosenberg SA. Overview of interleukin-2 as an immunotherapeutic agent. Semin Surg Oncol 1989;5:385-390.
56. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-384.
57. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:1169-1188.
58. Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. J Immunol 1986;137:3675-3680.
59. Mule JJ, Yang JC, Afreniere RL, Shu SY, Rosenberg SA. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 1987;139:285-294.
60. Papa MZ, Mule JJ, Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Cancer Res 1986;46:4973-4978.
61. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 1987;79:1067-1075.
62. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002;72:856-863.
63. Kasaian MT, et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002;16:559-569.
64. Parrish-Novak J, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408:57-63.
65. Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004;172:2048-2058.
66. Wang G, et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003;63:9016-9022.
67. Ma HL, et al. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol 2003;171:608-615.
68. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
69. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 2001;193:F23-F26.
70. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001;97:339-345.
71. Coussens LM, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999;13:1382-1397.
72. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481-490.
73. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000;248:171-183.
74. Blaser MJ, Chyou PH, Nomura A. Age at establishment of Helicobocter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res 1995;55:562-565.
75. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) 1998;63:854-865.
76. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999;190:1375-1382.
77. Engle SJ, et al. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res 2002;62:6362-6366.
78. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T. Transforming growth factor beta 1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 1999;59:3379-3386.
79. Moore RJ, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999;5:828-831.
80. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-740.
81. Lattanzio G, et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol 1997;151:689-696.
82. Shankaran V, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-1111.
83. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 1995;27:79-85.
84. Scholl SM, et al. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 1994;86:120-126.
85. Nowicki A, et al. Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int J Cancer 1996;65:112-119.
86. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-501.
87. Wong GH, Elwell JH, Oberley LW, Goeddel DV. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 1989;58:923-931.
88. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002;13:135-141.
89. Tselepis C, et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002;21:6071-6081.
90. Wu S, et al. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 1993;53:1939-1944.
91. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184-190.
92. Weichselbaum RR, et al. Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol 2002;3:665-671.
93. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987;329:630-632.
94. Baxevanis CN, Voutsas IF, Tsitsilonis OE, Tsiatas ML, Gritzapis AD, Papamichail M. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice. Eur J Immunol 2000;30:1957-1966.
95. Smyth MJ, Kelly JM, Baxter AG, Korner H, Sedgwick JD. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med 1998;188:1611-1619.
96. Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 1999;59:4516-4518.
97. Battegay EJ, Raines EW, Colbert T, Ross R. TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. J Immunol 1995;154:6040-6047.
98. Leber TM, Balkwill FR. Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer 1998;78:724-732.
99. Rosen EM, et al. Tumor necrosis factor stimulates epithelial tumor cell motility. Cancer Res 1991;51:5315-5321.
100. Roberts RA, Kimber I. Cytokines in non-genotoxic hepatocarcinogenesis. Carcinogenesis 1999;20:1397-1401.
101. Knight B, et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000;192:1809-1818.
102. Kitakata H, Nemoto-Sasaki Y, Takahashi Y, Kondo T, Mai M, Mukaida N. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res 2002;62:6682-6687.
103. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 2003;4:565-573.
104. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147.
105. Lee WY, Fischer SM, Butler AP, Locniskar MF. Modulation of interleukin-1 alpha mRNA expression in mouse epidermis by tumor promoters and antagonists. Mol Carcinog 1993;7:26-35.
106. Oberyszyn TM, Sabourin CL, Bijur GN, Oberyszyn AS, Boros LG, Robertson FM. Interleukin-1 alpha gene expression and localization of interleukin-1 alpha protein during tumor promotion. Mol Carcinog 1993;7:238-248.
107. La E, Muga SJ, Locniskar MF, Fischer SM. Altered expression of interleukin-1 receptor antagonist in different stages of mouse skin carcinogenesis. Mol Carcinog 1999;24:276-286.
108. Stevenson FT, Turck J, Locksley RM, Lovett DH. The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein. Proc Natl Acad Sci USA 1997;94:508-513.
109. Vanhamme L, Marshall GM, Schuh AC, Breitman ML, Vogt PK. Tumor necrosis factor alpha and interleukin 1 alpha induce anchorage independence in v-jun transgenic murine cells. Cancer Res 1993;53:615-621.
110. Vidal-Vanaclocha F, Amezaga C, Asumendi A, Kaplanski G, Dinarello CA. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res 1994;54:2667-2672.
111. Vidal-Vanaclocha F, Alvarez A, Asumendi A, Urcelay B, Tonino P, Dinarello CA. Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. J Natl Cancer Inst 1996;88:198-205.
112. Vidal-Vanaclocha F, et al. IL-18 regulates IL-1 beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 2000;97:734-739.
113. Tomimatsu S, Ichikura T, Mochizuki H. Significant correlation between expression of interleukin-1 alpha and liver metastasis in gastric carcinoma. Cancer 2001;91:1272-1276.
114. Iizuka N, et al. Interleukin-1 receptor antagonist mRNA expression and the progression of gastric carcinoma. Cancer Lett 1999;142:179-184.
115. El-Omar EM, et al. The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature 2001;412:99.
116. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999;20:46-52.
117. Hahne M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-1366.
118. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996;56:4791-4798.
119. Reimer T, et al. FasL : Fas ratio - a prognostic factor in breast carcinomas. Cancer Res 2000;60:822-828.
120. Soubrane C, Mouawad R, Antoine EC, Verola O, Gil-Delgado M, Khayat D. A comparative study of Fas and Fas-ligand expression during melanoma progression. Br J Dermatol 2000;143:307-312.
121. Restifo NP. Countering the 'counterattack' hypothesis. Nat Med 2001;7:259.
122. Ferrara N, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442.
123. Toi M, Taniguchi T, Yamamoto Y, Kurisaki T, Suzuki H, Tominaga T. Clinical significance of the determination of angiogenic factors. Eur J Cancer 1996;32A:2513-2519.
124. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001;23:263-272.
125. Gabrilovich DI, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-1103.
126. Oyama T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998;160:1224-1232.
127. Rafii S. Vaccination against tumor neovascularization: promise and reality. Cancer Cell 2002;2:429-431.
128. Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol 2001;186:153-168.
129. + T cells. J Immunol 1992;149:949-956.
130. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002;2:46-53.
131. Won J, Kim H, Park EJ, Hong Y, Kim SJ, Yun Y. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy. Cancer Res 1999;59:1273-1277.
132. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001;7:1118-1122.
133. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002;196:119-127.
134. Newport MJ, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996;335:1941-1949.
135. + T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice. Cancer Res 1998;58:5795-5802.
136. Agarwala SS, Kirkwood JM. Update on the role of adjuvant Interferon for high risk melanoma. Forum (Genova) 2000;10:230-239.
137. Pizzocaro G, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001;19:425-431.
138. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-219.
139. Guilhot F, Lacotte-Thierry L. Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase. Hematol Cell Ther 1998;40:237-239.
140. Borden EC. Gene regulation and clinical roles for interferons in neoplastic diseases. Oncologist 1998;3:198-203.
141. Meseri A, et al. Natural-killer cell activity and cytogenetic response in chronic myelogenous leukemia treated with alpha-interferon. Br J Haematol 1991;78:585-586.
142. Molldrem JJ, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-1023.
143. Wu CJ, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000;106:705-714.
144. Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia 1998;12:860-864.
145. Kirkwood JM, Strawderman MH, Emstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
146. Lafuma A, et al. Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma. Eur J Cancer 2001;37:369-375.
147. Agarwala SS, Kirkwood JM. Interferons in the therapy of solid tumors. Oncology 1994;51:129-136.
148. Kirkwood JM, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/ QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1 694/S9512/C509801. J Clin Oncol 2001;19:2370-2380.
149. Kirkwood JM, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001;19:1430-1436.
150. Pehamberger H, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998;16:1425-1429.
151. Altare F, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998;280:1432-1435.
152. Rook AH, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999;94:902-908.
153. + T cells in melanoma patients receiving interleukin 12. Cancer Res 2000;60:3559-3568.
154. Rosenberg SA, et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 1999;163:1690-1695.
155. Lee P, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001;19:3836-3847.
156. + melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 2001;7:895s-901s.
157. Coughlin CM, et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998;101:1441-1452.
158. Wigginton JM, et al. IFN-gamma and Fas/ FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001;108:51-62.
159. Soiffer R, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998;95:13141-13146.
160. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte -macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000;60:3239-3246.
161. Salgia R, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003;21:624-630.
162. Jaffee EM, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-156.
163. Rosenberg SA. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am 2000;6:S2-S7.
164. Rosenberg SA, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-632.
165. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6:S55-S57.
166. Atkins MB, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116.
167. Rosenberg SA, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
168. Rosenberg SA, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-975.
169. Dudley ME, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854.
170. Vincenti F, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338:161-165.
171. Waldmann TA, O'Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998;10:507-512.
172. Waldmann TA, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 1993;82:1701-1712.
173. Bienvenu J, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001;2:378-384.
174. Tsimberidou AM, Giles FJ. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther 2002;2:277-286.
175. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998;10:573-580.
176. Nestle FO, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
177. Banchereau J, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-6458.
178. Nanni P, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001;194:1195-1205.
179. Overwijk WW, Theoret MR, Restifo NP. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am 2000;6:S76-S80.
180. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002;13:169-183.
181. Bowne WB, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999;190:1717-1722.
182. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6:S11-S14.
183. Rosenberg SA, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-1166.
184. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995;122:254-261.
185. Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 1997;89:1616-1620.
186. Golomb HM, et al. Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b. Semin Oncol 1988;15:7-9.
187. Umeda T, Niijima T. Phase II study of alpha Interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer 1986;58:1231-1235.
188. Shepherd FA, et al. Prospective randomized trial of two dose levels of interferon alpha with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J Clin Oncol 1998;16:1736-1742.
189. Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998;16:1479-1489.
190. Trillet-Lenoir V, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-324.
191. Morse MA, et al. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol 2000;18:3883-3893.
192. Marroquin CE, et al. Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J Immunother 2002;25:278-288.
193. Biron CA. Role of early cytokines, including alpha and beta interferons (IFN-alpha/ beta), in innate and adaptive immune responses to viral infections. Semin Immunol 1998;10:383-390.
194. + blood dendritic cells are potent producers of IFN-alpha in response to in vitro HIV-1 infection. J Immunol 1994;152:4649-4662.
195. Siegal FP, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-1837.
196. Santini SM, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000;191:1777-1788.
197. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461-470.
198. Egle A, et al. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. Eur J Immunol 1996;26:3119-3126.
199. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999;189:1451-1460.
200. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-5161.
201. Coughlin CM, et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9:25-34.
202. Angiolillo AL, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:155-162.
203. Dinney CP, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998;58:808-814.
204. Ishikawa R, Biron CA. IFN induction and associated changes in splenic leukocyte distribution. J Immunol 1993;150:3713-3727.
205. Ahmed R. Tickling memory T cells. Science 1996;272:1904.
206. Smyth MJ, et al. Sequential production of interferon-gamma by NK1. 1 (+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 2002;99:1259-1266.
207. Fallarino F, Gajewski TF. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol 1999;163:4109-4113.
208. + T cells. Cancer Res 2003;63:4095-4100.